Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
diagnostics
3
×
indiana blog main
indiana top stories
life sciences
merck
national
national blog main
national top stories
new york blog main
new york top stories
3
×
novartis
3
×
pfizer
3
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
alzheimer's disease
cancer
cystic fibrosis
deals
gilead sciences
hepatitis b
immunotherapy
What
bio
drug
roundup
acquisitions
biggest
ceo
patients
advantages
albert
bar
bourla
brings
build
buy
company
company’s
crispr
daniel
debut
dyne’s
expect
future
gamble
gilead
imports
maker
maps
market
measured
medco’s
microbiome
mover
moves
new
openly
o’day
payers
pfizer
pfizer’s
physicians
Language
unset
unknown
Current search:
diagnostics
×
pfizer
×
novartis
×
" new york top stories "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More